Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

Breast Cancer Research

Table 3 Trends in hazard ratios for breast cancer mortality associated with hormone receptor status and different demographic and clinical characteristics

	ER+/PR+		ER+/PR-		ER-/PR+		ER-/PR-
Characteristics	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
Age at diagnosis, per 5 years^a	1.05	1.04–1.06	1.07	1.04–1.09	1.07	1.03–1.10	1.06	1.05–1.07
Diagnosis year, per year^b	0.93	0.92–0.94	0.92	0.90–0.94	0.95	0.91–0.98	0.96	0.95–0.97
Tumor stage^c	2.33	2.20–2.46	2.29	2.09–2.51	2.55	2.19–2.96	2.06	1.94–2.18
Tumor size (cm)^d	1.27	1.24–1.30	1.29	1.24–1.34	1.33	1.25–1.41	1.22	1.20–1.25
Axillary lymph node status^e	1.71	1.65–1.78	1.55	1.46–1.66	1.61	1.44–1.80	1.64	1.58–1.70
Tumor grade^f	1.62	1.55–1.70	1.49	1.36–1.63	1.72	1.46–2.03	1.24	1.16–1.32

^aFive-year categories. Reference = 30 to <35 years. HRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). ^bReference = 1990. HRs adjusted for age at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). ^cReference = stage 1. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Stage unknown, n = 4,728. ^dCategories = 0 to <1, 1 to <2, 2 to <3, 3 to <4, 4 to <5, 5 to <10, ≥10 cm. Reference = 0 to <1 cm. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Size unknown, n = 7,196. ^eCategories = 0, 1 to 3, 4 to 10, ≥11. Reference = 0. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, grade, and surgical and radiation treatment. Nodal status unknown, n = 22,394. ^fReference = grade 1. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, lymph node status, and surgical and radiation treatment. Grade unknown, n = 24,544. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.

ISSN: 1465-542X